Journal
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Volume 127, Issue 3, Pages 163-177Publisher
WILEY
DOI: 10.1111/bcpt.13427
Keywords
amylin; amylin receptor agonists; calcitonin receptor agonists; energy balance; metabolic disease; salmon calcitonin
Categories
Funding
- Novo Nordisk A/S
- Swiss National Science Foundation (SNF) [31003 A_175458]
- LifePharm Centre for In Vivo Pharmacology
Ask authors/readers for more resources
The prevalence of obesity and associated comorbidities such as type 2 diabetes and cardiovascular disease is increasing globally. Body-weight loss reduces the risk of morbidity and mortality in obese individuals, and thus, pharmacotherapies that induce weight loss can be of great value in improving the health and well-being of people living with obesity. Treatment with amylin and calcitonin receptor agonists reduces food intake and induces weight loss in several animal models, and a number of companies have started clinical testing for peptide analogues in the treatment of obesity and/or type 2 diabetes. Studies predominantly performed in rodent models show that amylin and the dual amylin/calcitonin receptor agonist salmon calcitonin achieve their metabolic effects by engaging areas in the brain associated with regulating homeostatic energy balance. In particular, signalling via neuronal circuits in the caudal hindbrain and the hypothalamus is implicated in mediating effects on food intake and energy expenditure. We review the current literature investigating the interaction of amylin/calcitonin receptor agonists with neurocircuits that induce the observed metabolic effects. Moreover, the status of drug development of amylin and calcitonin receptor agonists for the treatment of metabolic diseases is summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available